Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present CASI Pharmaceuticals, Inc. (NASDAQ: CASI).

Full DD Report for CASI

You must become a subscriber to view this report.


Recent News from (NASDAQ: CASI)

Week In Review: China Pharmas Announce Deals Worth $1.5 Billion
Deals and Financings WuXi AppTec (SHA: 603259), China's largest CRO/CMO, completed a $1 billion IPO on the Hong Kong markets, pricing the offering in the middle of the expected range. In May, WuXi became a public company by completing a $328 million IPO in Shanghai. Since the offering, the...
Source: SeekingAlpha
Date: December, 10 2018 00:48
CASI Pharmaceuticals' EVOMELA approved in China
CASI Pharmaceuticals (NASDAQ: CASI ) has received National Medical Products Administration ("NMPA") approval of Melphalan Hydrochloride For Injection (EVOMELA®), for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patient...
Source: SeekingAlpha
Date: December, 03 2018 08:23
CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (Trademark: EVOMELA®)
ROCKVILLE, Md. , Dec. 3, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in China and throughout the...
Source: PR Newswire
Date: December, 03 2018 08:12
RHT, GNW, WFT, ACB among midday movers (10/29/2018)
Gainers: Red Hat (NYSE: RHT ) +45% . Diana Containerships (NASDAQ: DCIX ) +24%  CASI Pharmaceuticals (NASDAQ: CASI ) +21% . Evogene (NYSE: EVGN ) +19%  Cooper Tire & Rubber Company (NYSE: CTB ) +18% . LM Funding America (NASDAQ: LMFA ) +17% . Stoneridge (NYSE: SRI ) +...
Source: SeekingAlpha
Date: October, 29 2018 12:47
Week In Review: Innovent Completes $421 Million Hong Kong IPO; Will Start Trading Next Week
Deals and Financings Innovent Biologics has priced its Hong Kong IPO to raise $421 million, very close to the top of the expected range. The company set its offering price at HK$13.98, just below the top of the range. The successful IPO shows investors are still interested in young China bio...
Source: SeekingAlpha
Date: October, 28 2018 11:37
Factors of Influence in 2018, Key Indicators and Opportunity within Steelcase, SecureWorks, Cleveland-Cliffs, Tredegar, Warrior Met Coal, and CASI Pharmaceuticals - New Research Emphasizes Economic Growth
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Steelcase Inc. (NYSE:SCS), SecureWorks Corp. (NASDAQ:SCWX), Cleveland-Cli...
Source: GlobeNewswire
Date: August, 27 2018 08:20
CASI Pharmaceuticals reports Q2 results
CASI Pharmaceuticals ( CASI -0.7% ) Q2 results : Revenues: $0; Net Loss: ($5.9M); Loss Per Share: ($0.07) (-75.0%); Quick Assets: $66.2M. More news on: CASI Pharmaceuticals, Healthcare stocks news, Earnings news and commentary, Read more ...
Source: SeekingAlpha
Date: August, 14 2018 09:36
CASI Pharmaceuticals Announces Second Quarter And First Half 2018 Financial And Business Results
ROCKVILLE, Md. , Aug. 14, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and thr...
Source: PR Newswire
Date: August, 14 2018 07:00
Free Pre-Market Technical Recap on Axovant Sciences and Three Additional Biotech Stocks
Stock Research Monitor: BPMC, CASI, and PTI LONDON, UK / ACCESSWIRE / July 20, 2018/ If you want a free Stock Review on AXON sign up now at www.wallstequities.com/registration . Research coverage has been initiated by WallStEquities.com on Axovant Sciences Ltd (NASDAQ: AXON ), Bluepr...
Source: ACCESSWIRE IA
Date: July, 20 2018 07:35
CASI pharmaceuticals added to Russell 2000®, 3000® and Microcap® indexes
CASI Pharmaceuticals ( CASI -1.2% ) announces that the company has been added to the Russell 2000 ® , 3000 ® and Microcap ® Indexes. More news on: CASI Pharmaceuticals, Read more ...
Source: SeekingAlpha
Date: July, 03 2018 13:57

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-144.254.254.494.00275,811
2018-12-134.304.304.394.12267,477
2018-12-123.994.324.383.9001513,852
2018-12-113.983.854.033.82117,602
2018-12-103.943.893.983.74214,706

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1448,35383,78057.7143Short
2018-12-1333,23556,95258.3562Short
2018-12-1248,923145,81133.5523Cover
2018-12-1126,26145,95957.1401Short
2018-12-1029,64352,95655.9767Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CASI.


About CASI Pharmaceuticals, Inc. (NASDAQ: CASI)

Logo for CASI Pharmaceuticals, Inc. (NASDAQ: CASI)

Not available

 

Contact Information

 

 

Current Management

  • Ken Ren / CEO
  • Sara Capitelli / CFO
  • Cynthia Wu / General Counsel

Current Share Structure

  • Market Cap: $625,985,145 - 05/14/2018
  • Issue and Outstanding: 79,641,876 - 03/28/2018

 


Recent Filings from (NASDAQ: CASI)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: May, 14 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 23 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 17 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: April, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 29 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 23 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 20 2018

 

 


Daily Technical Chart for (NASDAQ: CASI)

Daily Technical Chart for (NASDAQ: CASI)


Stay tuned for daily updates and more on (NASDAQ: CASI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CASI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CASI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CASI and does not buy, sell, or trade any shares of CASI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/